Frazier Lifesciences Acquisition Corporation Unit
FLACU
FLACU was delisted on the 22nd of November, 2022.
0 hedge funds and large institutions have $0 invested in Frazier Lifesciences Acquisition Corporation Unit in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 14 closing their positions.
100% less funds holding
Funds holding: 14 → 0 (-14)
100% less capital invested
Capital invested by funds: $31M → $0 (-$31M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 14
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$15.2M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$9.98M |
| 3 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$3.04M |
| 4 |
HF
HRT Financial
New York
|
-$866K |
| 5 |
TAL
TIG Advisors LLC
New York
|
-$679K |
FLACU Hedge Fund Activity: Q4 2022 in Review
0 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Frazier Lifesciences Acquisition Corporation Unit (FLACU) for Q4 2022, worth a combined $0 — down 100% from $31M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of FLACU and 0 opened new positions — a net loss of 14 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Frazier Life Sciences Management, exiting entirely with an estimated $15.2M sold.
- 0 institutional investors held Frazier Lifesciences Acquisition Corporation Unit (FLACU) as of Q4 2022, down from 14 in Q3 2022.
- Funds reported $0 of Frazier Lifesciences Acquisition Corporation Unit stock for Q4 2022, down 100% quarter-over-quarter.
- 0 funds opened new Frazier Lifesciences Acquisition Corporation Unit positions in Q4 2022 and 14 closed out, a net change of -14 holders.
- The largest Frazier Lifesciences Acquisition Corporation Unit seller in Q4 2022 was Frazier Life Sciences Management, an estimated $15.2M sold.
Based on aggregated 13F filings for Q4 2022.